In the field of anti-obesity new drug research and development, the two sides will carry out in-depth cooperation, jointly promote the intelligent upgrading of drug research and development, and efficiently complete the research and development of original new drugs.
In recent years, the pharmaceutical industry has set off a boom in AI-enabled innovative drug research and development. AI drug research and development, specifically, introduces artificial intelligence technology in the relevant application scenarios in the process of innovative drug research and development, so as to achieve the short-term and low-cost development of new drugs. At present, AI technology has emerged in the fields of drug target discovery, drug candidate molecular mining, compound screening, and new drug indications discovery.
Top multinational pharmaceutical companies have already laid out AI pharmaceutical technology, and from 2021-200 million dollars in 2021-2022. With AI enabling the research and development of new drugs, Chinese local pharmaceutical companies and Biotech also accelerated the entry, and the number of related technical cooperation showed a blowout trend.
The majority of domestic applications are small-molecule drugs, and mainly concentrated in the field of drug discovery, to realize the ability of large-scale platform pharmaceutical. In April this year, Shenzhen Potential Technology and Enhua Pharmaceutical first reached a strategic cooperation with Enhua Pharmaceutical to jointly promote the research and development of small molecule drugs in the central nervous field. After that, Jingtai Technology announced the small molecule innovative drug research and development work with Federal Pharmaceutical for chronic autoimmune diseases. Just two months later, Jingtai Technology has reached a cooperation with Hisun Pharmaceutical in the field of chemical synthesis.
The letter li Thai cooperation with alpha molecules, the letter li Thai drug discovery, development and clinical transformation ability, and alpha molecular biological computing, AI and original biotechnology, further enhance the efficiency and the success rate of new drug development, promote the industrialization upgrade in the international and domestic market, speed up the discovery of potential anti-obesity target drug molecules, achieve a win-win situation in the field of new drug research and development.
Obesity is a common chronic disease, often accompanied by many serious metabolic complications, such as hypertension, hyperglycemia, hyperlipidemia, and more. There are currently more than 700 million obese people worldwide, and the prevalence rate is still rising. Obesity has become a major public health problem that harms global health.
According to the Report on Nutrition and Chronic Diseases of Chinese Residents (2020), the rate of overweight / obesity among urban and rural age groups continues to rise, with the rate of overweight and obesity among Chinese residents aged 18 and above being 34.3 percent and 16.4 percent, respectively, with the total of more than 50 percent.
In 2030, China expects the prevalence of combined overweight / obesity in adults to reach 65.3%, and the medical costs attributable to overweight / obesity in China will reach 418 billion yuan, accounting for about 21.5% of the country's total medical costs.
At present, there are very few oral small-molecule drugs to treat obesity worldwide, and there is still much room for improvement in efficacy and safety. Based on the cooperation of superior resources and core technologies, Xinitai and Alpha Molecule organically integrate cutting-edge biotechnology and industrialization resources. It is reported that this is the first foreign cooperation of Xintai layout AI drug research and development track.
